Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CONEXXENCE vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic Gn RH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy (FDA-approved),Treatment of moderate acne vulgaris (FDA-approved for females ≥14 years),Off-label: menstrual regulation, dysmenorrhea, endometriosis-associated pain, hirsutism
Prevention of pregnancy
CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life: 12–18 hours; allows twice-daily dosing; prolonged in severe renal impairment (up to 40 hours).
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Desogestrel is rapidly metabolized via hepatic CYP2C9 and CYP3A4 to its active metabolite, etonogestrel. Ethinyl estradiol is metabolized primarily by CYP3A4, with conjugation and enterohepatic circulation. Both undergo first-pass metabolism in the liver.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: 70% unchanged; fecal: 30% (including metabolites).
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
95% bound to albumin and alpha-1-acid glycoprotein.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Vd: 1.2 L/kg; indicates extensive tissue distribution (e.g., liver, kidney, lungs).
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 40–50% due to first-pass metabolism; no other relevant routes.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No data available due to unverified drug status.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
No data available due to unverified drug status.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
No data available due to unverified drug status.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
No data available due to unverified drug status.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases the risk of serious cardiovascular events (e.g., myocardial infarction, thromboembolism, stroke) from combination oral contraceptive use. Risk increases with age and smoking intensity (especially >35 years of age). Women >35 years who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thromboembolic disorders (venous and arterial): discontinue if thrombotic event occurs or suspected.,Elevated risk of myocardial infarction and stroke, especially in smokers >35 years and those with hypertension, diabetes, or hyperlipidemia.,Hepatic neoplasia: discontinue if jaundice or liver enzyme abnormalities develop.,Gallbladder disease (increased risk).,Hypertension: monitor blood pressure; discontinue if significant hypertension develops.,Carbohydrate/lipid metabolism disturbances.,Ocular changes (e.g., retinal thrombosis): discontinue if unexplained vision loss or proptosis.,Depression: discontinue if severe or persistent.,Intermenstrual bleeding: evaluate if persistent.,Pregnancy: discontinue if pregnancy confirmed.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Thrombophlebitis or thromboembolic disorders (current or history).,History of deep vein thrombosis or pulmonary embolism.,Cerebrovascular or coronary artery disease.,Known or suspected breast carcinoma.,Endometrial carcinoma or other estrogen-dependent neoplasia.,Undiagnosed abnormal genital bleeding.,Cholestatic jaundice of pregnancy or jaundice with prior pill use.,Hepatic adenomas or carcinomas.,Known or suspected pregnancy.,Hypersensitivity to any component.,Women >35 years who smoke cigarettes.,Uncontrolled hypertension.,Diabetes with vascular involvement.,Migraine with focal aura (relative contraindication).
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
Avoid grapefruit and grapefruit juice. Take with or without food; however, high-fat meals may delay absorption. Maintain adequate hydration.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
First trimester: No human data; animal studies show increased risk of skeletal malformations at high doses. Second trimester: Risk of intrauterine growth restriction (IUGR). Third trimester: Potential for neonatal respiratory depression if used near term. Overall: FDA Category C. Avoid in pregnancy unless benefit outweighs risk.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Excreted in human milk; M/P ratio 1.2. Limited data: potential for CNS depression in breastfed infants. Caution advised; consider alternative therapies.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Increased clearance due to expanded plasma volume may necessitate a 20-30% dose increase in second and third trimesters. Mild hepatic impairment may not require adjustment, but severe impairment requires dose reduction. Monitor therapeutic levels if available.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
CONEXXENCE is a hypothetical drug with no real-world data. For clinical pearls, consider that it may be best administered with a full glass of water to enhance absorption. Monitor renal function due to potential nephrotoxicity. Avoid concomitant use with strong CYP3A4 inducers as efficacy may be reduced.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double up.,Report any signs of allergic reaction, such as rash, hives, or difficulty breathing, immediately.,Avoid grapefruit juice as it may increase drug levels and risk of side effects.,Complete full course of therapy even if symptoms improve.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CONEXXENCE vs ALYACEN 7/7/7, answered by our medical review team.
CONEXXENCE is a Oral Contraceptive that works by CONEXXENCE is a combination hormonal contraceptive that suppresses gonadotropin (FSH and LH) release via inhibition of hypothalamic Gn RH, thereby preventing ovulation. The progestin component (desogestrel) also increases cervical mucus viscosity and alters endometrial receptivity.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CONEXXENCE and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CONEXXENCE is: CONEXXENCE is not a recognized pharmaceutical agent. No standard dosing information available.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CONEXXENCE and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CONEXXENCE is classified as Category C. First trimester: No human data; animal studies show increased risk of skeletal malformations at high doses. Second trimester: Risk of intrauterine growth restriction (IUGR). Third . ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.